Response to initial reinduction regimens overall and by reinduction regimen
| First reinduction regimen . | Overall N = 81 . | CR n = 66 . | PR n = 7 . | Progressive disease n = 5 . | Unknown n = 3 . |
|---|---|---|---|---|---|
| ALK inhibitor | 37/81 (46%) | 34/37 (92%) | 1/37 (2.7%) | 0/37 (0%) | 2/37 (5%) |
| Brentuximab | 19/81 (23%) | 14/19 (74%) | 3/19 (16%) | 2/19 (11%) | 0/19 (0%) |
| Chemotherapy without targeted agent | 12/81 (15%) | 9/12 (75%) | 0/12 (0%) | 2/12 (17%) | 1/12 (8%) |
| Chemotherapy with targeted agent | 9/81 (11%) | 7/9 (78%) | 2/9 (22%) | 0/9 (0%) | 0/9 (0%) |
| Vinblastine | 4/81 (4.9%) | 2/4 (50%) | 1/4 (25%) | 1/4 (25%) | 0/4 (0%) |
| Patients achieving response | 66/81 (66%) | 7/81 (7%) | 5/81 (6%) | 3/81 (4%) |
| First reinduction regimen . | Overall N = 81 . | CR n = 66 . | PR n = 7 . | Progressive disease n = 5 . | Unknown n = 3 . |
|---|---|---|---|---|---|
| ALK inhibitor | 37/81 (46%) | 34/37 (92%) | 1/37 (2.7%) | 0/37 (0%) | 2/37 (5%) |
| Brentuximab | 19/81 (23%) | 14/19 (74%) | 3/19 (16%) | 2/19 (11%) | 0/19 (0%) |
| Chemotherapy without targeted agent | 12/81 (15%) | 9/12 (75%) | 0/12 (0%) | 2/12 (17%) | 1/12 (8%) |
| Chemotherapy with targeted agent | 9/81 (11%) | 7/9 (78%) | 2/9 (22%) | 0/9 (0%) | 0/9 (0%) |
| Vinblastine | 4/81 (4.9%) | 2/4 (50%) | 1/4 (25%) | 1/4 (25%) | 0/4 (0%) |
| Patients achieving response | 66/81 (66%) | 7/81 (7%) | 5/81 (6%) | 3/81 (4%) |